FcRn(新生儿Fc受体)

为什么FcRn值得重点关注?
新生儿 Fc 受体(Neonatal Fc receptor, FcRn)在人体多种组织中广泛表达,是调控IgG半衰期和循环的重要分子。FcRn由FCGRT(α链)与B2M(β链)组成异源二聚体,通过pH依赖性方式选择性结合IgG,避免其在溶酶体中降解,从而延长抗体在体内的循环时间。此外有研究表明,FcRn与IgG和血清白蛋白的结合位点并不相同,因此FcRn与IgG结合不会受到血清蛋白的干扰。
FcRn延长半衰期的作用机制
FcRn延长半衰期的作用机制
FcRn延长半衰期的作用机制
FcRn延长半衰期的作用机制
FcRn与配体IgG和白蛋白的作用位点不同
FcRn与配体IgG和白蛋白的作用位点不同
在抗体药物研发中,FcRn结合特性用于评估抗体半衰期,指导Fc工程优化和候选分子筛选;在自身免疫疾病药物开发中,FcRn可以作为靶点,通过促进致病IgG降解,为类风湿性关节炎、系统性红斑狼疮等疾病提供新治疗策略。同时,它还参与免疫调节和白蛋白递送,为免疫治疗和药物递送平台开发提供支持。
FcRn与配体IgG和白蛋白的作用位点不同
FcRn与配体IgG和白蛋白的作用位点不同

FcRn主要研究应用:

抗体半衰期评估与Fc工程优化
评估FcRn介导的抗体循环能力,预测抗体半衰期、筛选Fc突变体,评估候选抗体的PK特性与可开发性。
FcRn抑制剂筛选与活性表征
用于抗体、Fc片段、多肽及蛋白类FcRn抑制剂的开发与评价,评价FcRn-IgG结合阻断能力,助力自身免疫疾病药物研发。
白蛋白结合与递送研究
研究FcRn介导的白蛋白回收与转运机制,支持白蛋白融合蛋白及相关药物递送研究。

为什么选择ACROBiosystems的FcRn产品?

• 全流程覆盖:提供蛋白、试剂盒、稳定细胞株,支持从分子筛选到临床前研究全流程。
• 验证数据可靠:通过SPR、BLI、SEC-MALS、FACS等多种方法验证结合活性与功能,确保实验决策可靠。
• 高质量与稳定供应:严格质控确保高批间一致性,支持全球商业化项目和IND申报。

产品优势

FcRn蛋白
FcR蛋白
应用场景
Fc-FcRn结合分析
半衰期优化
白蛋白研究
种属交叉验证
主要优势
SEC-MALS验证>95%纯度
SPR&BLI验证亲和力
低内毒(<10 EU/mg)可选
FCGRT & B2M异源二聚体构象,HEK293表达,确保正确折叠及翻译后修饰
多种属:涵盖Human、Mouse、Cynomolgus / Rhesus macaque等多物种,支持种属交叉实验
结合检测试剂盒(TR-FRET)
结合检测试剂盒(TR-FRET)
应用场景
抑制剂筛选
Fc结合力比较
抗体半衰期早期评价
主要优势
操作简单快速:免洗,1小时即可完成操作,支持高通量筛选
验证数据全面:使用各种抗体亚型和抗体药物进行验证
批间一致性高:严格控制原材料和成品质量,确保稳定供应
与SPR结果趋势一致,验证检测准确性
过表达细胞株
过表达细胞株
应用场景
抗体筛选(Fc结合能力比较)
半衰期早期评价
FcRn功能验证
主要优势
传代稳定性经验证,稳定传代>20代
原始细胞株获合法商业许可,可提供全球商业授权支持服务
全面的应用数据,支持方法开发与验证
支持IND申报

产品列表

FcRn重组蛋白
TR-FRET结合检测试剂盒
过表达细胞株

验证数据

FcRn异源二聚体结构经SEC-MALS验证

FcRn异源二聚体结构经SEC-MALS验证

The purity of Canine FCGRT&B2M Heterodimer Protein, His Tag&Tag Free (Cat. No. FCM-C52W8) is more than 90% and the molecular weight of this protein is around 43-60 kDa verified by SEC-MALS.

Human FcRn与Herceptin亲和力经SPR验证

Human FcRn与Herceptin亲和力经SPR验证

Immobilized Biotinylated Human FCGRT&B2M Heterodimer Protein, His,Avitag (Cat. No. FCM-H82W7) on SA Chip can bind Herceptin® with an affinity constant of 0.267 μM as determined in a SPR assay (Biacore 8K) (QC tested).

申请Protocol

Mouse FcRn与Herceptin亲和力经SPR验证

Mouse FcRn与Herceptin亲和力经SPR验证

Mouse FCGRT&B2M Heterodimer Protein, His Tag (Cat. No. FCM-M52W8) captured on NTA-Series S sensor chip can bind Herceptin with an affinity constant of 2.52 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

申请Protocol

FcRn与Herceptin亲和力经BLI验证

FcRn与Herceptin亲和力经BLI验证

Loaded Cynomolgus / Rhesus macaque FCGRT&B2M Heterodimer Protein, His Tag&Strep II Tag (Cat. No. FCM-C5284 ) on SA Biosensor via Biotin his antibody, can bind Herceptin with an affinity constant of 0.13 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

申请Protocol

FCGRT&B2M二聚体与白蛋白结合经BLI验证

FCGRT&B2M二聚体与白蛋白结合经BLI验证

Loaded Biotinylated Human FCGRT&B2M Heterodimer Protein, His,Avitag (Cat. No. FCM-H82W7) on SA Biosensor, can bind Human Serum Albumin, His Tag (Cat. No. HSA-H5220) with an affinity constant of 0.647 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

申请Protocol

FcRn TR-FRET试剂盒性能验证

抗体半衰期评价:检测3款FDA获批抗体药物,IC50趋势与SPR亲和力常数和文献报道的体内半衰期一致,可用于抗体半衰期的早期评价。
FcRn与Herceptin亲和力经BLI验证

The half-lives of these 3 monoclonal antibodies currently in clinical use generally correlate with the binding affinity to FcRn. The kit (Cat.No.FRT-01) has been used to detect 3 FDA approved antibody drugs of different binding affinity to FcRn, and the IC50 trends are consistent with affinity constant from SPR as well as the actual in vivo half-life published.

申请Protocol
抑制剂筛选验证:可有效检测FcRn抑制剂,Efgartigimod及其类似物均显示明确FcRn阻断活性。
FCGRT&B2M二聚体与白蛋白结合经BLI验证

The kit (Cat.No.FRT-01) is suitable for the detection of FcRn inhibitors. It shows that both Efgartigimod and its biosimilar, Human IgG1 Fc (C103S, M135Y, S137T, T139E, H316K, N317F) His Tag (Cat. No. IG1-H52H8) exhibit good inhibitory activity in this TR-FRET competition assay.

申请Protocol

FcRn稳定细胞株功能验证:适用于细胞水平功能评价

FcRn稳定细胞株功能验证:适用于细胞水平功能评价

FACS assay shows that FITC-Labeled Human IgG1 Fc (C103S, M135Y, S137T, T139E, H316K, N317F) Protein, His Tag (Cat. No. IG1-HF2H3) can bind to HEK293/Human FcRn (FCGRT & B2M) Stable Cell Line. HEK293/Human FcRn (FCGRT & B2M) Stable Cell Line (Cat. No. CHEK-ATP079) was red line, negative control HEK293 cells was grey line(QC tested).

申请Protocol

相关参考文献

  • 1. The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. The Journal of Clinical Inveatigation. 1972, 51:2916–27. Authors:Jones EA, Waldmann TA.

  • 2. FcRn: the neonatal Fc receptor comes of age. Nature Reviews Immunology. 2007,7:715–725. Authors:Derry C. Roopenian, Shreeram Akilesh.

  • 3. Howard. FcRn expression in cancer: Mechanistic basis and therapeutic opportunities. Journal of Controlled Release. 2021, 337 :248–257. Authors:Imke Rudnik-Jansen, Kenneth A.

  • 4. Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis. Frontiers in Immunology. 2020, 10. Authors:Karissa L. Gable, Jeffrey T. Guptill.

  • 背景
  • 产品优势
  • 产品列表
  • 验证数据
  • 资源分享
  • 相关推荐
  • 相关参考文献